Clinical Trial Update: A Prospective, Randomized Multicenter, Open-label Comparison of Preoperative Trastuzumab Emtansine (T-DM1) With or Without Standard Endocrine Therapy vs. Trastuzumab With Standard Endocrine Therapy Given for Twelve Weeks in Patients With Operable HER2+/HR+ Breast Cancer Within the ADAPT Protocol. [Phase 2]

View source ↗

Summary

This Phase 2 randomized open-label trial within the ADAPT protocol compares preoperative trastuzumab emtansine (T-DM1) with or without standard endocrine therap…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Endocrine therapy
• Trastuzumab (trastuzumab)
• Trastuzumab emtansine (ado-trastuzumab emtansine)

Snippet

Sponsor: West German Study Group | Conditions: Breast Cancer | Phase 2 | Status: COMPLETED